Biovail Corp. International deal

BVF reacquired the U.S. rights to its once-daily controlled release formulation of Diltiazem HCI from Hoechst-Roussel Pharmaceuticals Inc. The Toronto company said it decided to reacquire the product after Hoechst announced it would acquire controlling interest in Marion Merrell Dow Inc., which also sells the cardiovascular drug under the name Cardizem CD. ...